Clinical Trial
doi: 10.1016/0022-510x(72)90021-4.Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase
- PMID:4560435
- DOI: 10.1016/0022-510x(72)90021-4
Item in Clipboard
Clinical Trial
Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase
J L Reid et al. J Neurol Sci.1972 Sep.
Display options
Format
Display options
Format
No abstract available
Similar articles
- Modification of levodopa effect by systemic decarboxylase inhibition.Mars H.Mars H.Arch Neurol. 1973 Feb;28(2):91-5. doi: 10.1001/archneur.1973.00490200039004.Arch Neurol. 1973.PMID:4683155No abstract available.
- Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.Andrews CJ, Somerville B.Andrews CJ, et al.Med J Aust. 1974 Mar 23;1(12):429-32.Med J Aust. 1974.PMID:4598384Clinical Trial.No abstract available.
- [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].Birkmayer W, Linauer W, Mentasti M, Riederer P.Birkmayer W, et al.Wien Med Wochenschr. 1974 Jun 1;124(22):340-4.Wien Med Wochenschr. 1974.PMID:4275492Clinical Trial.German.No abstract available.
- Augmenting the action of levodopa.Rao SK, Vakil SD, Calne DB, Hilson A.Rao SK, et al.Postgrad Med J. 1972 Nov;48(565):653-6. doi: 10.1136/pgmj.48.565.653.Postgrad Med J. 1972.PMID:4568331Free PMC article.Review.
- Recent advances in the treatment of Parkinsonism with drugs.Rinne UK.Rinne UK.Acta Neurol Scand Suppl. 1972;51:59-103.Acta Neurol Scand Suppl. 1972.PMID:4576076Review.No abstract available.
Cited by
- "On-off" phenomena related to high plasma levodopa.Claveria LE, Calne DB, Allen JG.Claveria LE, et al.Br Med J. 1973 Jun 16;2(5867):641-3. doi: 10.1136/bmj.2.5867.641.Br Med J. 1973.PMID:4714848Free PMC article.
- Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS.Pinder RM, et al.Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001.Drugs. 1976.PMID:782834Review.No abstract available.
- Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ.Katzenschlager R, et al.J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7. doi: 10.1136/jnnp.2003.028761.J Neurol Neurosurg Psychiatry. 2004.PMID:15548480Free PMC article.Clinical Trial.
- Gout induced by L-dopa and decarboxylase inhibitors.Calne DB, Fermaglich J.Calne DB, et al.Postgrad Med J. 1976 Apr;52(606):232-3. doi: 10.1136/pgmj.52.606.232.Postgrad Med J. 1976.PMID:1273018Free PMC article.
- Clinical pharmacokinetics of levodopa in parkinson's disease.Bianchine JR, Shaw GM.Bianchine JR, et al.Clin Pharmacokinet. 1976;1(5):313-38. doi: 10.2165/00003088-197601050-00001.Clin Pharmacokinet. 1976.PMID:797502Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources